Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegozafermin - 89bio

Next Previous
Drug Profile

Pegozafermin - 89bio

Alternative Names: BIO-89-100; TEV 47948

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Developer 89bio
  • Class Antihyperlipidaemics; Antineoplastics; Fibroblast growth factors; Hepatoprotectants
  • Mechanism of Action Fibroblast growth factor 21 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertriglyceridaemia; Non-alcoholic steatohepatitis
  • Phase I/II Non-alcoholic fatty liver disease
  • Preclinical Liver cancer

Most Recent Events

  • 27 Mar 2024 Pegozafermin - 89bio receives Priority Medicine (PRIME) status for Non-alcoholic steatohepatitis in Europe
  • 12 Mar 2024 Phase-III clinical trials in Non-alcoholic steatohepatitis in USA (SC) (NCT06318169)
  • 29 Feb 2024 89bio plans a phase III ENLIGHTEN-Fibrosis trial for Nonalcoholic steatohepatitis (NASH) in the first quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top